Personalized dosing of vedolizumab or ustekinumab for IBD
Part of Digestive system clinical trials.
This trial tests whether a personalized dosing method (using your own drug levels) can help people with Crohn's or ulcerative colitis maintain better control with vedolizumab or ustekinumab. It aims to see if adjusting doses based on your individual needs leads to fewer flare-ups and better outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ulcerative colitis or Crohn's disease (diagnosed at least 3 months ago).
- You are 18 years or older.
- You have been on a stable dose of vedolizumab (Entyvio) or ustekinumab (Stelara) for at least 3 months.
- Your disease is stable (mild or no symptoms, with a fecal calprotectin level of 200 or less).
- You do not have a stoma or pouch, and you are not pregnant or nursing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
This study tests the drug vedolizumab in adults with moderate to severe ulcerative colitis or Crohn's disease. It aims to see how well the medicine works in a community (non-hospital) setting.
This study tests whether a medicine called vedolizumab can help heal all layers of the bowel wall in Crohn's disease. It uses a special ultrasound to see inside the bowel, aiming for deeper healing than usual.
This study builds a prediction model to estimate how people with ulcerative colitis may respond to certain medicines. It may help doctors choose the most effective treatment sooner.
This research study tests whether taking vedolizumab injections less often (every 4 weeks instead of every 2 weeks) can still keep your Crohn's or colitis in remission. If you are already well-controlled on standard vedolizumab, this study may help you and others by reducing the number of injections needed.
This study compares two ways of taking the IBD medicine vedolizumab (injecting under the skin versus through an IV line). You'll use a smartphone app to report your symptoms, so you can participate from home and help doctors learn which option works better.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.